La cadena de opciones muestra datos clave de las opciones de acciones de CASI Pharmaceuticals a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para CASI Pharmaceuticals..

CASI Pharmaceuticals (NASDAQ:CASI) Bolsa, Cadena de Opciones

CASI Pharmaceuticals

CASI Pharmaceuticals Inc is a biopharmaceutical company that focuses on commercializing therapeutics and pharmaceutical products. The products include injections for patients who are suffering from leukemias and lymphomas. The EVOMELA injection is used as a conditioning treatment before autologous stem cell transplant for patients with multiple myeloma. The company products include CID-103, CNCT19, EVOMELA, MARQIBO, ZEVALIN, ENMD-2076 and others. The majority of the revenue is generated from the product sales of EVOMELA.

CASI Pharmaceuticals, Inc. - Ordinary Shares

CASI Pharmaceuticals Inc

Casino Guichard-Perrachon SA

CASINO GUICHARD PERRACHON by Casino Guichard Perrachon SA

Casino Guichard-Perrachon SA ADR

CASIO COMPUTER CO LTD by Casio Computer Co., Ltd.

Casio Computer Co Ltd

CASIO COMPUTER UNSP/ADR by Casio Computer Co., Ltd.

Press Releases

CASI PHARMACEUTICALS TO PARTICIPATE IN THE 2024 H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE

News

CASI Pharmaceuticals Receives CTA Approval From China's NMPA for CID-103 in Immune Thrombocytopenia

Earnings

CASI Pharmaceuticals Announces Third Quarter 2024 Business and Financial Results

CASI Announces First Patient Dosed in Phase 1/2 Clinical Trial of CID-103 in Immune Thrombocytopenia

CASI Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Business and Financial Results

CASI Pharmaceuticals Announces Receipt of An Updated Non-Binding Proposal to Acquire Entire China Business of the Company

CASI Pharmaceuticals Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement

CASI Pharmaceuticals Enters Into Definitive Agreement for the Divestiture of Assets in China

CASI Pharmaceuticals Announces First Quarter 2025 Business and Financial Results

CASI Pharmaceuticals Provides Business and Clinical Update

CASI

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Aligos Therapeutics

ALX Oncology Holdings Inc. - Common Stock

ALX Oncology Holdings

Burning Rock Biotech Limited - American Depositary Shares

Burning Rock Biotech

CollPlant Biotechnologies Ltd. - Ordinary Shares

CollPlant Biotechnologies

Clene

Chemomab Therapeutics Ltd. - American Depositary Shares

Chemomab Therapeutics

Coeptis Therapeutics Holdings, Inc. - Common Stock

Coeptis Therapeutics

Curis

Dyadic International, Inc. - Common Stock

Dyadic International

FibroBiologics

FibroGen

Generation Bio

CytoMed Therapeutics Limited - Ordinary Shares

CytoMed Therapeutics

MiNK Therapeutics

Karyopharm Therapeutics Inc. - Common Stock

Karyopharm Therapeutics

Kezar Life Sciences

Lantern Pharma

OnKure Therapeutics, Inc. - Class A Common Stock

OnKure Therapeutics

OSR Holdings

Passage Bio

Pluri

Radiopharm Theranostics Limited - American Depositary Shares

Comments

CASI Pharmaceuticals

CASI Pharmaceuticals (CASI) Opciones

CASI Pharmaceuticals (NASDAQ:CASI) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL